703 patents currently held
517 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5 more records may belong here and await a decision; they are not counted.
The next term ends in Nov 2026. from the record
Of the 517 now held by other companies, 377 name Roche Diabetes Care Inc. as their current owner, and 140 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
136
Ending by 2030
Nov 2026
Next term end
586
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Nov 2032 · High confidence
Also notable
Ends Nov 2026 · High confidence
Also notable
Ends Jul 2030 · High confidence
Laboratory Sample Distribution System, Laboratory System and Method of Operating
US 9,239,335
Cited by 99 later US patents, top 5% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2032.
Cartridge Device for Blood Analysis
US 7,901,629
The most cited patent in this portfolio, cited by 100 later US patents, top 10% of utility patents granted in 2011 in our data. Protection runs to 2026.
Set of Oligonucleotide Probes as Well as Methods and Uses Thereto
US 8,445,206
Cited by 50 later US patents, top 25% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
Formerly held, still cited
Notable
Ends Nov 2027 · High confidence
Cited by 251 later US patents, top 5% of utility patents granted in 2010 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
now held by Roche Diabetes Care, Inc.
Also notable
Ends Jun 2031 · High confidence
Cited by 174 later US patents, top 5% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
now held by Roche Diabetes Care, Inc.
Also notable
Ends Apr 2031 · High confidence
Cited by 65 later US patents, top 5% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
now held by Roche Diabetes Care, Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 14, 2026The maintenance fee for Device for Mounting a Plurality of Actuator Modules (US 10,288,634) comes due Nov 14, 2026. Unpaid by May 14, 2027, it lapses early.
- 6 fees due Dec 2 to 25, 2026 · next Dec 2
- 16 fees due Jan 2 to 25, 2027 · next Jan 2
- 8 fees due Feb 8 to 28, 2027 · next Feb 8
- 13 fees due Mar 5 to 24, 2027 · next Mar 5
- 16 fees due Apr 3 to 29, 2027 · next Apr 3
- 7 fees due May 5 to 26, 2027 · next May 5
- 11 fees due Jun 1 to 30, 2027 · next Jun 1
- 8 fees due Jul 2 to 30, 2027 · next Jul 2
- 12 fees due Aug 6 to 27, 2027 · next Aug 6
- 12 fees due Sep 1 to 30, 2027 · next Sep 1
- 11 fees due Oct 2 to 30, 2027 · next Oct 2
- 1 fee due Nov 7, 2027The maintenance fee for Supplementing Measurement Results of Automated Analyzers (US 11,977,601) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
- Oct 21Assignment recorded on 1 record: Roche Diagnostics GmbH to Roche Diagnostics Operations, Inc. Recorded Oct 21, 2026, executed Dec 5, 2024. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76455, frame 514.
- Oct 13Assignment recorded on 1 record: Roche Diagnostics GmbH to Roche Diagnostics Operations, Inc. Recorded Oct 13, 2026, executed May 8, 2023. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76356, frame 586.
- 14 of the patents on this record were granted since Aug 16, 2026
- 14 terms have ended since Aug 16, 2026
What they patent
The 5 largest of its 586 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| In-Vitro Diagnostic Analysis Method and System | 5 in force | to Jun 2035 |
| Display Screen or Portion Thereof with Graphical User Interface and Computer Icons | 4 in force | to Oct 2035 |
| Blood Testing Apparatus | 4 in force | to Sep 2034 |
| Recombinantly Produced Neutral Protease Originating from Paenibacillus Polymyxa | 4 in force | to Jul 2033 |
| Handling of Sample Tubes Comprising Geometric Tube Data | 4 in force | to Aug 2032 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,901,629 | Cartridge Device for Blood Analysis In force · High confidence | In force | High confidence | |
| US D672,052 | Sample Cup In force · High confidence | In force | High confidence | |
| US 7,491,495 | Adsorption of Nucleic Acids to a Solid Phase In force · High confidence | In force | High confidence | |
| US 7,416,706 | Level Sensor Apparatus for Detecting Contact of a Pipetting Needle with a Liquid in a Vessel In force · High confidence | In force | High confidence | |
| US 7,947,494 | Fusion Protein Comprising an E. Coli Chaperone Protein and a Human Chaperone Protein In force · High confidence | In force | High confidence | |
| US 8,247,206 | Fusion Protein Comprising an Escherichia Coli Chaperone Protein and a Human Chaperone Protein In force · High confidence | In force | High confidence | |
| US 7,981,635 | Cleavage of Precursors of Insulins by a Variant of Trypsin In force · High confidence | In force | High confidence | |
| US 9,528,986 | Immunological Test Element with Control Zone for Identifying Hook Effect In force · High confidence | In force | High confidence | |
| US 9,220,452 | Plastic Injection-Moulded Part with Embedded Component In force · High confidence | In force | High confidence | |
| US 7,759,470 | Labeling Reagent In force · High confidence | In force | High confidence |
Also on record, not counted in the 703: 517 patents in force now held by others · 892 patents ended · 247 applications pending · 645 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.